ERRATUM

Comparison of a soluble co-formulation of insulin degludec/insulin aspart vs biphasic insulin aspart 30 in type 2 diabetes: a randomised trial

Leo Niskanen, Lawrence A Leiter, Edward Franek, Jianping Weng, Taner Damci, Manuel Muñoz-Torres, Jean-Paul Donnet, Lars Endahl, Trine Vang Skjøth and Allan Vaag

The journal and the authors apologise for errors in Table 2 of this article that was published in the August issue (vol **167**, pp 287–294). The *n* values were incorrectly published. The correct values are presented below and the table is published in full below.

European Journal of Endocrinology **167** 453

Table 2 Observed mean changes from baseline HbA1c, FPG and body weight. Data are observed as mean (s.d.) for all randomised subjects (full analysis set).

	<i>n</i>	Baseline ^a	Week 16 ^b	Change from baseline
HbA1c (%)				
IDegAsp	61	8.5 (1.2)	6.7 (1.0)	−1.8 (1.1) ^c
AF	59	8.5 (0.9)	6.6 (0.6)	−1.9 (1.1) ^c
BIAsp 30	62	8.6 (1.0)	6.7 (0.7)	−1.8 (0.9) ^c
FPG (mmol/l)				
IDegAsp	61	11.5 (2.6)	6.4 (2.2)	−5.1 (2.9)
AF	59	11.8 (2.9)	6.5 (1.9)	−5.3 (3.0)
BIAsp 30	62	11.7 (3.1)	7.5 (2.1)	−4.3 (3.0)
Body Weight (kg)				
IDegAsp	61	87.5 (16.3)	88.6 (16.9)	1.1 (2.8)
AF	59	84.9 (14.3)	85.6 (14.9)	0.7 (2.5)
BIAsp 30	62	91.8 (13.5)	93.2 (13.1)	1.4 (3.2)

^aValues at randomisation.

^bLast observation carried forward.

^c% points.